Study wrapper · #1061
Beyond weight loss: How metabolism in human adipocytes is shaped by GLP-1R agonists and dual GIPR/GLP-1R agonists.
Curto R, Giglione C, Cannarella R, et al. Pharmacological research. 2026.
DOI: 10.1016/j.phrs.2026.108278PubMed: 42229677
Editor's note
A narrative review of preclinical adipocyte biology for GLP-1R and dual GIPR/GLP-1R agonists, with tirzepatide as the named dual agonist. It synthesizes mechanism-level animal and in vitro findings rather than clinical outcomes, and the authors themselves flag that these models may not translate to human adipose tissue. Readers can read it as background on possible tissue-level mechanisms, not as clinical evidence.
Plain-language abstract
This narrative review summarizes preclinical evidence on how GLP-1 receptor agonists and the dual GIP/GLP-1 agonist tirzepatide act on fat cells, beyond their weight-loss effects. The authors note that most mechanistic data come from animal or in vitro models and call for more work in human-derived cells.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Mixed
Sleeve gastrectomy versus tirzepatide to improve survival among patients with stage 5 CKD: A Markov decision analysis.
American journal of surgeryn=——2026
Mixed
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Journal of chromatography. An=——2026